Global Pulmonary Sarcoidosis Pipeline Insight Market Report 2021 Featuring Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, & SarcoMed USA – ResearchAndMarkets.com | Financial Buzz

Global Pulmonary Sarcoidosis Pipeline Insight Market Report 2021 Featuring Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, & SarcoMed USA – ResearchAndMarkets.com

The “Pulmonary Sarcoidosis – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Pulmonary Sarcoidosis – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Pulmonary Sarcoidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Sarcoidosis R&D. The therapies under development are focused on novel approaches for Pulmonary Sarcoidosis.

Pulmonary Sarcoidosis Emerging Drugs Chapters

This segment of the Pulmonary Sarcoidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pulmonary Sarcoidosis Emerging Drugs

CMK 389: Novartis

CMK 389 acts as inhibitors of Interleukin 18. It is being developed by Novartis for Pulmonary sarcoidosis and is currently in phase II stage of development.

ATYR1923: aTyr Pharma

ATYR1923 is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need. ATYR1923 works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. ATYR1923 is conducting a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that cause progressive fibrosis of the lung.

Pulmonary Sarcoidosis: Therapeutic Assessment

This segment of the report provides insights about the different Pulmonary Sarcoidosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Pulmonary Sarcoidosis

There are approx. 10+ key companies which are developing the Pulmonary Sarcoidosis. The companies which have their Pulmonary Sarcoidosis drug candidates in the most advanced stage, i.e. Phase III include, Corbus Pharmaceuticals.

Phases

This report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Pulmonary Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pulmonary Sarcoidosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Sarcoidosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Sarcoidosis drugs.

Pulmonary Sarcoidosis Report Insights

  • Pulmonary Sarcoidosis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Pulmonary Sarcoidosis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Scenario and Emerging Therapies:

  • How many companies are developing Pulmonary Sarcoidosis drugs?
  • How many Pulmonary Sarcoidosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Pulmonary Sarcoidosis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Sarcoidosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Pulmonary Sarcoidosis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Novartis
  • aTyr Pharma
  • Relief Therapeutics
  • AI Therapeutics
  • SarcoMed USA

Key Products

  • CMK389
  • ATYR1923
  • RLF-100
  • LAM-001
  • SM001

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/o6l2rj

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!